[go: up one dir, main page]

PE20070093A1 - Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c - Google Patents

Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c

Info

Publication number
PE20070093A1
PE20070093A1 PE2006000420A PE2006000420A PE20070093A1 PE 20070093 A1 PE20070093 A1 PE 20070093A1 PE 2006000420 A PE2006000420 A PE 2006000420A PE 2006000420 A PE2006000420 A PE 2006000420A PE 20070093 A1 PE20070093 A1 PE 20070093A1
Authority
PE
Peru
Prior art keywords
methanamine
benzofuran
dihydro
derivatives
formula
Prior art date
Application number
PE2006000420A
Other languages
English (en)
Inventor
Jiu Ai
Yanning Lin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20070093A1 publication Critical patent/PE20070093A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A DERIVADOS DIHIDROBENZOFURANOS DE FORMULA (I) DONDE n ES 1 o 2; R2 Y R3 SON INDEPENDIENTEMENTE H, METILO, ETILO, 2-FLUOROETILO, 2,2-DIFLUOROETILO O CICLOPROPILO; R1 ES H, HALOGENO, OH, CN, H, ALQUILO INFERIOR, ENTRE OTROS; Ar ES FENILO OPCIONALMENTE SUSTITUIDO CON UNO O MAS Rx; DONDE Rx ES HALOGENO, OH, CN, ALQUILO(C1-C4), ENTRE OTROS; y ES 0 A 3. SON COMPUESTOS PREFERIDOS: (+)-1-(7-FENIL-2,3-DIHIDRO-1-BENZOFURAN-2-IL)METANAMINA, (+)-1-[7-(2-METILFENIL)-2,3-DIHIDRO-1-BENZOFURAN-2-IL]METANAMINA, (+)-1-[7-(2-FLUOROFENIL)-2,3-DIHIDRO-1-BENZOFURAN-2-IL]METANAMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPUESTO DE FORMULA (I); B) COMPUESTOS DE FORMULA IIa, IIIb, IVb, ENTRE OTROS Y C) EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES. DICHOS COMPUESTOS ACTUAN COMO AGONISTAS DEL RECEPTOR 5-HT2C SIENDO UTILES EN EL TRATAMIENTO DE LA ESQUIZOFRENIA, DEPRESION, DESORDEN BIPOLAR
PE2006000420A 2005-04-22 2006-04-21 Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c PE20070093A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67399605P 2005-04-22 2005-04-22

Publications (1)

Publication Number Publication Date
PE20070093A1 true PE20070093A1 (es) 2007-02-07

Family

ID=36809596

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000420A PE20070093A1 (es) 2005-04-22 2006-04-21 Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c

Country Status (13)

Country Link
US (1) US20060258739A1 (es)
EP (1) EP1871356A1 (es)
JP (1) JP2008538577A (es)
CN (1) CN101203216A (es)
AR (1) AR056979A1 (es)
AU (1) AU2006239942A1 (es)
BR (1) BRPI0610037A2 (es)
CA (1) CA2604759A1 (es)
GT (1) GT200600165A (es)
MX (1) MX2007012936A (es)
PE (1) PE20070093A1 (es)
TW (1) TW200719886A (es)
WO (1) WO2006116170A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
US7470799B2 (en) * 2005-04-22 2008-12-30 Wyeth Dihydrobenzofuran derivatives and uses thereof
GT200600160A (es) * 2005-04-22 2007-03-14 Tratamiento del dolor
RU2007139541A (ru) * 2005-04-22 2009-05-27 Вайет (Us) Производные хромана и хромена и их применение
KR20080009295A (ko) * 2005-04-22 2008-01-28 와이어쓰 벤조디옥산 및 벤조디옥솔란 유도체 및 이의 용도
GT200600164A (es) * 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
GT200600163A (es) * 2005-04-22 2007-03-14 Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
BRPI0609952A2 (pt) * 2005-04-24 2010-05-11 Wyeth Corp métodos para modular a função da bexiga
JPWO2007083729A1 (ja) * 2006-01-20 2009-06-11 株式会社大阪チタニウムテクノロジーズ 酸化チタン製造方法
EP1998764A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware Methods for treating cognitive and other disorders
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US8399410B2 (en) 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
ES2677548T3 (es) 2008-05-21 2018-08-03 Ferring B.V. Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
CN102267989B (zh) * 2011-06-03 2014-06-11 浙江工业大学 一种2-甲基苯并呋喃类化合物及其制备与应用
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN118393052B (zh) * 2024-06-24 2024-09-24 山东则正医药技术有限公司 一种硫酸羟氯喹中有关物质的检测方法及应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) * 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4210754A (en) * 1977-02-01 1980-07-01 Hoffmann-La Roche Inc. Morpholino containing benzamides
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
FR2508035A1 (fr) * 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
ATE177101T1 (de) * 1992-12-17 1999-03-15 Pfizer Pyrrolopyrimidine als crf antagonisten
US6005109A (en) * 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
US6103900A (en) * 1992-12-17 2000-08-15 Pfizer Inc Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
EP0674624B1 (en) * 1992-12-17 1999-01-20 Pfizer Inc. Pyrazoles having crf antagonist activity
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
PT639374E (pt) * 1993-06-28 2002-07-31 American Home Prod Novos tratamentos utilizado derivados fenetilo
US5705646A (en) * 1993-09-30 1998-01-06 Pfizer Inc. Substituted pyrazoles as CRF antagonists
US5668145A (en) * 1993-11-12 1997-09-16 Pfizer Inc. Amino-substituted pyrazoles having CRF antagonistic activity
CA2192928C (en) * 1994-06-15 2010-10-26 Hidenori Ogawa Benzoheterocyclic derivatives
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
TW359669B (en) * 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6194407B1 (en) * 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
FR2788176B1 (fr) * 1998-12-30 2001-05-25 Thomson Csf Dispositif a ondes acoustiques guidees dans une fine couche de materiau piezo-electrique collee par une colle moleculaire sur un substrat porteur et procede de fabrication
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
ATE257834T1 (de) * 1999-06-30 2004-01-15 Bristol Myers Squibb Co Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe
AU2002338333A1 (en) * 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
US20040235856A1 (en) * 2003-04-25 2004-11-25 Pfizer Inc Treatment of incontinence
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) * 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
GT200600164A (es) * 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
TW200716583A (en) * 2005-04-22 2007-05-01 Wyeth Corp Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
RU2007139541A (ru) * 2005-04-22 2009-05-27 Вайет (Us) Производные хромана и хромена и их применение
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
KR20080009295A (ko) * 2005-04-22 2008-01-28 와이어쓰 벤조디옥산 및 벤조디옥솔란 유도체 및 이의 용도
GT200600160A (es) * 2005-04-22 2007-03-14 Tratamiento del dolor
MX2007013024A (es) * 2005-04-22 2009-02-16 Wyeth Corp Tratamiento de abuso de drogas.
GT200600163A (es) * 2005-04-22 2007-03-14 Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
US7470799B2 (en) * 2005-04-22 2008-12-30 Wyeth Dihydrobenzofuran derivatives and uses thereof
BRPI0609952A2 (pt) * 2005-04-24 2010-05-11 Wyeth Corp métodos para modular a função da bexiga

Also Published As

Publication number Publication date
AR056979A1 (es) 2007-11-07
BRPI0610037A2 (pt) 2010-05-25
TW200719886A (en) 2007-06-01
JP2008538577A (ja) 2008-10-30
WO2006116170A1 (en) 2006-11-02
AU2006239942A1 (en) 2006-11-02
EP1871356A1 (en) 2008-01-02
GT200600165A (es) 2007-03-14
MX2007012936A (es) 2008-01-11
CA2604759A1 (en) 2006-11-02
US20060258739A1 (en) 2006-11-16
CN101203216A (zh) 2008-06-18

Similar Documents

Publication Publication Date Title
PE20070093A1 (es) Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
NZ525700A (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
EA200600190A1 (ru) Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона
EA200970928A1 (ru) Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
CR9910A (es) Antagonistas del receptor 3 de la histamina
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
PE20081377A1 (es) Compuestos de tiazol pirazolopirimidina
NO20062139L (no) Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
PE20140934A1 (es) Derivados de pirazol
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
GEP20146099B (en) Fused imidazole carboxamides as trpv3 modulators
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia

Legal Events

Date Code Title Description
FC Refusal